Stockscreener 앱 받기
8.29
0.96%
-0.08
시간 외 거래:
8.44
0.15
+1.81%
전일 마감가:
$8.37
열려 있는:
$8.35
하루 거래량:
4.15M
Relative Volume:
0.77
시가총액:
$2.11B
수익:
$874.84M
순이익/손실:
$263.86M
주가수익비율:
6.8905
EPS:
1.2031
순현금흐름:
$327.41M
1주 성능:
-8.09%
1개월 성능:
-7.99%
6개월 성능:
+18.94%
1년 성능:
-20.21%
1일 변동 폭
$8.215
$8.54
1주일 범위
$8.215
$9.07
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.29 | 2.13B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 재개 | Evercore ISI | Outperform |
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
BCRX Should I Buy - Intellectia AI
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
BioCryst director Amy McKee sells $100,284 in company shares - Investing.com UK
BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan
Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance
BCRX (NASDAQ) Form 144: Affiliate plans resale of 11,180 shares - Stock Titan
BioCryst’s SWOT analysis: rare disease stock eyes growth path By Investing.com - Investing.com Nigeria
BioCryst’s SWOT analysis: rare disease stock eyes growth path - Investing.com
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth beyond single product - Investing.com
BioCryst Pharmaceuticals’ SWOT analysis: stock gains ground on pediatric approval - Investing.com Nigeria
BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability - Investing.com UK
BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path By Investing.com - Investing.com Australia
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path - Investing.com
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
Responsive Playbooks and the BCRX Inflection - Stock Traders Daily
European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX) - Sahm
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Biocryst (BCRX) CLO sells 62,500 shares in pre-set 10b5-1 trade - Stock Titan
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case - Sahm
BioCryst Pharmaceuticals stock (US09058V1035): Shares surge 9% after earnings - AD HOC NEWS
BCRX Jumps As Price Target Hike Caps Busy Catalyst Week - StocksToTrade
62,500-share resale registered by BCRX insider (NASDAQ: BCRX) - Stock Titan
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 - The Manila Times
BioCryst Pharmaceuticals to Present New Research on Pediatric Hereditary Angioedema at ISPOR 2026 Conference - Quiver Quantitative
BioCryst to Present New Real-World Evidence Underscoring - GlobeNewswire
Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition - PR Newswire
Study: Kids with rare swelling disorder log 3x outpatient visits vs peers - Stock Titan
BioCryst Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BioCryst Q1 2026 slides: dual HAE strategy targets $1.8B revenue - Investing.com Canada
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up - Investing.com Nigeria
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up By Investing.com - Investing.com South Africa
BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed? - Yahoo Finance
State Street (NASDAQ: BCRX) holds 4.9% of BioCryst, 12.2M shares - Stock Titan
Influenza Therapeutics Market to Reach USD 12.94 Billion by 2033 - openPR.com
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing Deal - Yahoo Finance
European patients gain future access to HAE drug navenibart in $300M deal - Angioedema News
Is BioCryst Pharmaceuticals (BCRX) Pricing Reflect Its Pipeline Progress And Recent Share Performance Changes - Sahm
Number of shareholders of BioCryst Pharmaceuticals, Inc. – FWB:BO1 - TradingView
These analysts revise their forecasts on BioCryst Pharma after Q1 earnings - MSN
BioCryst Pharmaceuticals (NASDAQ:BCRX) Rating Lowered to Hold at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
BioCryst (BCRX) Q1 2026 Earnings Transcript - AOL.com
BCRX Adjusts FY26 Revenue Outlook with Key Estimates - GuruFocus
BioCryst (BCRX) Reports Q1 Revenue Growth Amid Significant Loss - GuruFocus
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
4.44%
자본화:
|
볼륨(24시간):